Abstract:
Background -Non-valvular atrial fibrillation (NVAF) is the most common arrhythmia. Patients with NVAF are at increased risk of stroke, therefore we evaluated the efficacy and safety of different approaches to prevent this major complication.
Methods and Results -We conducted electronic database searches of phase III randomized controlled trials (RCT). The groups were novel oral anticoagulants (NOAC), Watchman left atrial appendage occlusion device (DEVICE), and warfarin. Efficacy outcomes were stroke and/or systemic embolism (SSE), and all-cause mortality. Safety outcome was major bleeding and/or procedure related complications. A sub-group analysis of the elderly population was done.
We used random-effects model to compare pooled outcomes and tested for heterogeneity. Odds ratios (OR) and 95% confidence intervals (CI) were computed for each outcome. Seven RCTs (n=73,978) were included. There was a significant difference favoring NOAC for SSE (OR 0.84, 95% CI 0.72-0.97; p=0.01), all-cause mortality (OR 0.89, 95% CI 0.84-0.94; p<0.001) and safety outcomes (OR 0.79, 95% CI 0.65-0.97; p=0.026) compared to warfarin. No difference was seen between DEVICE and warfarin for efficacy endpoints, however DEVICE had more complications (OR 1.85, 95% CI 1.14-3.01; p=0.012). In the elderly (6 RCTs, n=30,699), SSE was favored with NOAC over warfarin (OR 0.77, 95% CI 0.68-0.87; p=<0.001). No evidence of significant publication bias was found.
Conclusions -NOAC is superior to warfarin for stroke prevention in NVAF. This benefit was also observed in the elderly population. DEVICE is a reasonable non-inferior alternative to warfarin for stroke prevention, but cautious use is essential given safety concerns. ignifican an ant t t pu pu publ bl blic ic icat at atio io ion n n bi bi bias as as w w was as as f f fou ou ound nd d. .
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Background
Non-valvular atrial fibrillation (NVAF) is the most common arrhythmia. 1 For individuals of European descent, the lifetime risk of developing AF after 40 years of age is 26% for men and 23% for women, 2 and these patients are at increased risk of stroke. The incidence of NVAF increases with age, and at the same time the elderly population is at increased risk of embolic and bleeding complications. Therefore, no matter what treatment option is chosen between rate or rhythm control, stroke prevention is essential.
Until recently, warfarin was largely the only option available for stroke prevention, and although it is an effective choice, it has many limitations, including constant monitoring, slow onset and offset of action, inter-individual variability in anticoagulant effect, narrow therapeutic index, food and drug interactions, and reduced synthesis of all vitamin K-dependent proteins. 3 Therefore, different strategies have been developed, including novel oral anticoagulants (NOAC) and left atrial appendage (LAA) occlusion devices. Despite these developments, the best strategy for stroke prevention remains to be fully elucidated, especially in the elderly.
Several NOACs are available that offer potential advantages over warfarin. Randomized controlled trials (RCTs) have shown that these medications are at least as safe and effective as warfarin for prevention of stroke and systemic embolism (SSE) in patients with NVAF. 4 The LAA is a site of major blood stasis during AF increasing the risk of thrombus formation and stroke, thus it has been a target for emerging technologies to prevent this disabling complication. Percutaneous LAA occlusion devices have been developed to overcome the aforementioned challenges. 5, 6 The only reported RCTs of LAA closure are the Watchman LAA System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT-AF) and the Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With onset and offset of action, inter-individual variability in anticoagulant effect, narr r row w w t t the he hera ra rape pe peut utic ndex, x, , food an a d dr drug interactions, and reduced sy ynt n he h sis of all vitamin K K-dependent proteins.
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Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL) trials evaluating the Watchman device (Boston Scientific, Natick, Massachusetts). 7, 8 These trials have demonstrated non-inferiority to adjusted-dose warfarin therapy.
Despite these advances, it is still uncertain what is the best strategy for stroke prevention in NVAF. To better assess the clinical implications of these strategies, we carried out a systematic review of the literature and a meta-analysis of randomized, clinical trials of NOACs and Watchman device compared to therapy with warfarin for the prevention of stroke in patients with NVAF, including a sub-group analysis of the elderly population.
Methods
Search strategy
We conducted electronic database searches of phase III RCTs, through a computerized literature Search terms keywords included: randomized controlled trial, atrial fibrillation, nonvalvular atrial fibrillation, stroke, apixaban, rivaroxaban, dabigatran, edoxaban, oral factor Xa
Methods
Search strategy
We We We c c conduct ted ed ed electronic database searches of pha ase e e III RCTs, thr hr rou o o gh g a computerized literature 12 Rivaroxaban versus warfarin in Japanese patients with atrial fibrillation (J-ROCKET AF), 13 PROTECT-AF, 7 and PREVAIL. 8 An additional search limited to the elderly population (>/= 75 years of age) with NVAF was done using the same criteria as above. Six phase III RCTs were found comparing NOACs and Watchman device to warfarin for stroke prevention in this population. The trials that had this information available were: RE-LY, ROCKET AF, ARISTOTLE, ENGAGE AF-TIMI 48, PROTECT-AF and PREVAIL. [9] [10] [11] 14 Elderly data for the Watchman device trials was only available for patients >/= 72 years old (Boston Scientific device report).
Inclusion Criteria
The PRISMA statement for reporting systematic reviews and meta-analyses of RCTs was applied to the methods for this study. 15 Studies included were required to meet the following specifications: (1) RCT design; (2) evaluation of patients with NVAF only; and (3) inclusion of subjects randomized only to NOACs or Watchman device versus warfarin. Two reviewers DFB and PV independently extracted data AF-TIMI 48 study (Edoxaban), 12 Rivaroxaban versus warfarin in Japanese patien en ents ts ts w w wit it ith h h at at atri ri ri l l al fibrilla ation (J (J-RO OCK C ET AF), 13 PROTECT-AF, 7 and nd PREVAIL. 8 An ad ad ddi di iti ti tion on onal al l se se sear ar arch ch ch li imi mi mite te ted d d to to o th th the el el elde de derly po o opu ula la lati ti tion on on (> >/= /= /= 7 7 75 5 5 ye ye year ar ars s of f f a a age ge ge) ) ) wi w w th th h N N NVA VA VAF F F wa wa was s do d ne using n t t the e e sam m me e e crit t ter er ria i i as ab ab a o ov ove e. a Six x x pha a ase e e II I II I I RC RC RCTs s we er ere e e foun n nd d d co co om m mparin n ng g g N N NO OA ACs s s
and Watc c chm h h an d d dev e ice e e to to to warfar ar arin i i for stroke pr p p ev ev even en enti t on in n n this p p pop p pul ul ulation. T T The h h t tri ri r als that had this n nfo fo orm rm rmat at atio io on n n a a ava va vail ilab ab able le le w w wer er ere: e: e: RE RE RE-LY LY LY, , , R R ROC OC OCKE KE KET T T AF AF AF, , , AR AR ARIS IS ISTO TO TOTL TL TLE, E, E, E E ENG NG NGAG AG AGE E E AF AF AF-T -T TIM IM IMI I I 48 48 48, , , from identified RCTs. Disagreements were resolved by consensus or, if necessary, by a third party NC.
Study endpoints
The primary endpoint was the incidence of SSE. The secondary endpoint was all-cause mortality.
The safety endpoint was adjudicated major bleeding during treatment and/or device-/procedurerelated complications (Table 1) .
Statistical analysis
We used a random-effects models to compare pooled outcomes. 16 The Cochran Q-test and the
Higgins I 2 -test were used for heterogeneity testing. 17 In trials with multiple treatment arms, we collapsed the data to compute an effective size and variance. All participants in the NOACs and
Device arms and all participants in the eligible control arms were pooled for analysis. To address publication bias, we used the funnel plots. 18 If any bias was observed, further bias quantification was measured using the Begg-Mazumdar test, 19 Egger test, 20 and the Duval and Tweedie´s trim and fill test. 21, 22 Sensitivity analyses were performed by using the one-study-out method, addressing the influence of each study by testing whether deleting each in turn would significantly change the pooled results of the meta-analysis. Chronological cumulative analyses
were assessed in the DEVICE group to test if the effect size and precision shifts changes based on the procedure experience seen with time. 17 The statistical analysis was performed by the Comprehensive Meta-analysis version 2.0 software.
Results
Study Selection and Characteristics
The search strategy identified a total of 1,069 potential articles ( Figure 1 ). After removing duplicates and articles not meeting inclusion criteria, we screened 182 titles and abstracts. Of collapsed the data to compute an effective size and variance. All participants in the h NO NOAC ACs and
Device arms and all participants in the eligible control arms were pooled for analysis. To address pu publication bi bias, , w we us used d t the h fun unne el l plots. 18 If any bias w was as obser erved, d fur rth t er b bia i s qu quanti ifi f ca ati t on wa was measured using the Begg g-Mazumd m ar test, 19 Egger te test, 20 and the Duval and Twee eedie´s trim and fill tes e t. 21, 22 Sensi iti ivity ana aly lyses were per erform rmed by y us sing g the on o e-study-y-out t method, addressing the influence of each study by testing whether deleting each in turn would d
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http://circep.ahajournals.org/ Downloaded from these, 12 were selected for further review of eligibility. Finally, seven RCTs satisfied inclusion criteria, all of which were published in English. The baseline characteristics of the included trials are presented in Table 2 . Overall, the 7 RCTs enrolled a total of 73,978 patients. All the studies were phase III. The comparison groups included NOAC, the Watchman left atrial appendage occlusion device (DEVICE) and warfarin. The NOACs used in the RCTs were apixaban, rivaroxaban, dabigatran, and edoxaban. Duration of follow-up was more than 12 months in all trials. The anticoagulation strategy in the Watchman group was variable ( Figure 2 ). All 7 RCTs reported SSE and all-cause mortality for the primary endpoint. For the safety endpoint, the NOACs trials reported major bleeding, and DEVICE trials reported both major bleeding and device-/procedure-related complications. In terms of analysis, the different doses of the NOACs used in the trials were combined and analyzed as a single group.
Six RCTs were included in the analysis for the elderly ( Table 2 ). The 6 RCTs enrolled a total of 30,699 patients. All the studies were phase III. The comparison groups included NOAC, DEVICE and warfarin. The NOACs used in the RCTs were rivaroxaban, dabigatran, apixaban and edoxaban. The 6 RCTs reported SSE. No data was available for all-cause mortality and safety outcomes in the DEVICE group for the elderly, therefore only the primary endpoint was analyzed in this sub-group.
Quantitative Data Synthesis Primary endpoint
There were a total of 2,654 SSE in the entire group of patients: 3.5% (1,487/42,998) in the NOAC and 3.4% (25/732) in the DEVICE group. Overall, there was a significant difference favoring NOAC compared to warfarin for SSE (OR 0.84, 95% CI 0.72-0.97; p=0.01). No difference was observed between DEVICE and warfarin ( Figure 3 ).
device-/procedure-related complications. In terms of analysis, the different doses s s of of f the he e N N NOA OA OAC Cs used in the trials w were combined and analyzed as a s single group.
Six RC RC RCTs Ts Ts we we w re re re i i inc nc nclu lu lude de ed d d in in in t t the he he a a ana n n ly ly lysi si sis s s for r r th h he el el elde de derl rl rly y y (T T Tab ab able le le 2 2). ). ). Th Th T e 6 6 6 RC RC RCTs Ts T en en enro ro roll ll lled ed ed a a a o o ota tal l l of 30,699 99 p pat t tient ts s. All t t the he e studi di ies e w w were ph ph hase e e I II II. Th Th The c c co o ompa pa ar ri ison g gr grou ou oups ps ps inclu u ude de ded N N NOAC AC AC, DEVICE E E a a and wa wa arf r arin n n. . Th T T e NO O OAC A A s used in th th t e e e RC RC RCTs T wer er ere rivaroxa xa xaban, , dab ab abig g gat at atra r n, ap p pixaban an an and d d ed ed edox ox oxab ab aban an an. . . Th The e e 6 6 6 RC RC RCTs Ts Ts r r rep ep epor or orte te ted d d SS SS SSE. E. E. N N No o o da da data ta ta w w was as as a a ava va vail ilab ab able le e f f for or or a a all ll ll-ca ca caus us use e e mo mo mort rt rtal al a it it ity y y an an and d d
Secondary endpoint
All-cause mortality was 5,510 in the entire group of patients: 7.5% (3,212/42,978) in the NOAC and 3.8% (28/732) in the DEVICE group. There was a significant difference favoring NOAC over warfarin for all cause mortality (OR 0.89, 95% CI 0.84-0.94; p<0.001). No difference was seen between DEVICE and warfarin ( Figure 4 ).
Safety endpoint
There were 4,085 cases of major bleeding or device-/procedure-related complications in all enrolled patients. The proportions of safety endpoints were 5% (2,161/42,943) in the NOAC and 10.7% (78/732) in the DEVICE group. A significant difference favoring NOAC compared to warfarin was observed (OR 0.79, 95% CI 0.65-0.97; p=0.026). DEVICE was associated with more complications when compared to warfarin (OR 1.85, 95% CI 1.14-3.01; p=0.012) ( Figure   5 ).
Elderly -Primary endpoint
Six RCTs reported outcomes in the elderly population (n=30,699 patients). There were a total of 1,211 SSE in this group: 3.3% (544/16,280) in the NOAC and 11% (42/388) in the DEVICE group. There was a significant difference favoring NOAC over warfarin for SSE when compared to warfarin (OR 0.77, 95% CI 0.68-0.87; p=<0.001). No difference was seen between DEVICE and warfarin ( Figure 6 ).
Sensitivity analysis
Sensitivity analysis involving the removal of each of the RCTs (only done for NOAC vs. El El Elde de erl r y -Prim ima a ary y y en ndp dp point t t
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Cumulative analysis
Chronological cumulative analysis for each outcome did not find any significant change in the final effect overall outcomes (Supplemental Figure 2) .
Bias
Funnel plot did not show asymmetry suggesting bias for all endpoints except for all-cause mortality ( Figure 7 ). However, after quantifying the observed bias with others methods (BeggMazumdar, Egger and Duval and Tweedie´s trim and fill test) there was no evidence of publication bias (Supplemental Figure 3) .
Discussion
This meta-analysis involved 73,978 patients for the general analysis and 30,699 for the elderly evaluation, providing a comprehensive assessment of the risk-benefit profile for the use of NOAC or Watchman device compared to warfarin for stroke prevention in NVAF.
The main finding of this meta-analysis is that stroke prevention in NVAF is superior with NOAC compared to warfarin, as it showed lower SSE and all cause mortality while having a better safety profile, while no difference was found between DEVICE and warfarin. Nonetheless, there is a marginal benefit to lower SSE and mortality in the DEVICE versus warfarin group, which is not statistically significant probably because of the limited sample size of the PROTECT-AF and PREVAIL trials. Consequently, it is important to highlight that the Watchman device is a reasonable non-inferior alternative to warfarin for stroke prevention.
However, it must be taken into account the higher rate of complications found in the DEVICE group (related mainly to bleeding, mostly during the first 45 days post-implantation), which is probably determined by concomitant warfarin and aspirin use during this initial period.
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Additionally, the need for dual anti-platelets 6 months post-device implantation even if there is adequate LAA seal or the long-term addition of warfarin if no LAA seal is achieved, may weigh against preference for interventional LAA occlusion using this strategy in patients predisposed to bleeding ( Figure 2 ). Regarding procedure related complications, the PROTECT-AF trial reported serious pericardial effusion (n=22), and device embolization (n=3), while the PREVAIL trial reported device embolization (n=2), arteriovenous fistula (n=1), cardiac perforation (n=1), and serious pericardial effusion (n=1).
Previous meta-analyses are available comparing NOACs to warfarin, ilustrating similar results to our findings, including a favorable risk-benefit profile, with significant reductions in stroke and mortality. 4, 23, 24 However, to the best of our knowledge, this is the first time that the overall positive outcomes are reported to be dependent only by two trials (RELY and ARISTOTLE trials), as shown in the sensitivity study.
On the other hand, data on percutaneous devices for stroke prevention in NVAF is still very limited. The use of this technology remains controversial because of scarce literature on efficacy and safety. The available data have compared observational studies, finding noninferiority of LAA closure compared to medical management with warfarin for stroke prevention in patients with NVAF. 25 Hence, this is the first attempt to compare the different strategies for stroke prevention in NVAF based on RCTs, including pharmacological and structural approaches, providing also insights into the elderly population. Therefore, this meta-analysis provides unique evidence supporting the concept that anticoagulation with NOACs is probably the best option available today for stroke prevention in NVAF in an average bleeding risk population. In addition, these results illustrate that the use of NOACs not only provides practical advantages over Watchman troke and mortality. 4, 23, 24 However, to the best of our knowledge, this is the firs s st t ti ti time me e t t tha ha hat t t th th the overal ll po p p siti ive o out u comes are reported to be depen nde dent only by two trials ls ( ( (RELY and
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Limitations
Our meta-analysis has some limitations given major differences between therapies, patient demographics, therapies, and trial characteristics that might affect outcomes not accounted for in this analysis. First, population characteristics were quite different among the single studies and because this is a study-level meta-analysis, we were unable to confirm the overall results in specific subgroups of patients. Second, the definitions of composite endpoints for primary, secondary and safety outcomes differed across trials. Third, we evaluated a pharmacological approach with a non-pharmacological strategy, which have largely different efficacy and safety profiles, therefore the variability of approaches may be an important source of distortion in the observed point estimates. Fourth, the results of our meta-analysis are driven mainly by 5 large RCTs involving the NOACs, whereas fewer data is available on the Watchman device.
On the other hand, despite these limitations, the consistency of the magnitude and direction of the overall effect and the stability of the results after the sensitivity analyses support the robustness of the conclusions and make the overall estimates justified.
Conclusion
NOAC is superior to warfarin for the prevention of stroke and death in patients with NVAF. This stroke prevention benefit was also observed in a sub-group analysis of the elderly population.
DEVICE is a reasonable non-inferior alternative to warfarin for stroke prevention, but cautious use is essential given safety concerns. No definitive conclusion can be drawn in the elderly pecific subgroups of patients. Second, the definitions of composite endpoints for r pr prim mar ary y, , Events related to procedure-related complications (eg, seriou ou us s s pe pe peri ri rica ca card rd rdia ia i l effu fu usi sio on on, devi ic ce ce em m mbo bol l lization, pr ro oc o ed ed dure-relate e ed stro ro oke ke) ). ). Major b bl blee ee eding g g was s de de d fi fi fine ne n d as as as b b ble le leeding g g th t that res s l ul ulte te ted d d i in in death, wa wa was life-th th thre r atening, r re requ qu quir ir ired ed ed h hos os ospi pi pita ta tali li iza za zati ti tion on o o o or p p pro ro ol lo long ng n at at a io io on n n of of of ex e is isti ti tin ng ng h h ho ospi pi ita ta tali liza za zati t t on on on, re re resu su sult lt lted ed ed i i in n n pe pe perm rm rman an anen en ent t t impairment of a body TTR, Percent time in therapeutic INR range *15mg daily if creatinine clearance 30-49 ml/min †10mg daily if creatinine clearance 30-49ml/min ‡2.5-mg doses were used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg/dl or more. §For patients in either group, the dose was halved if any of the following characteristics were present at the time of randomization or during the study: estimated creatinine clearance of 30 to 50 ml/min, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine. 
